INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 178 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,243,152 | -19.3% | 43,063 | -1.9% | 0.01% | -16.7% |
| Q2 2023 | $2,778,988 | +16.9% | 43,888 | 0.0% | 0.01% | +20.0% |
| Q1 2023 | $2,376,536 | +66.7% | 43,888 | +62.9% | 0.01% | +66.7% |
| Q4 2022 | $1,425,665 | +25.8% | 26,940 | +10.7% | 0.00% | 0.0% |
| Q3 2022 | $1,133,000 | -84.2% | 24,340 | -80.6% | 0.00% | -82.4% |
| Q2 2022 | $7,164,000 | -13.0% | 125,493 | -6.7% | 0.02% | 0.0% |
| Q1 2022 | $8,233,000 | +27.5% | 134,553 | +9.1% | 0.02% | +41.7% |
| Q4 2021 | $6,455,000 | +105.4% | 123,327 | +46.4% | 0.01% | +71.4% |
| Q3 2021 | $3,142,000 | +7.2% | 84,260 | +17.4% | 0.01% | +16.7% |
| Q2 2021 | $2,931,000 | +20.3% | 71,797 | 0.0% | 0.01% | +20.0% |
| Q1 2021 | $2,436,000 | +6.7% | 71,797 | 0.0% | 0.01% | 0.0% |
| Q4 2020 | $2,283,000 | +218.0% | 71,797 | +156.5% | 0.01% | +150.0% |
| Q3 2020 | $718,000 | – | 27,991 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |